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Abstract 
Objective: To demonstrate the utility of pharmacogenomic (PGx) panel testing use versus single gene testing for a single indication. 
Panel testing may not only help further refine clinical decision making for the primary medical indication, it may uncover with one 
diagnostic test multiple PGx abnormalities, altering current and future therapy for other conditions. 
Summary: Breast cancer patient presented to the pharmacist PGx service to discuss results and to help determine best guidance for 
post-surgical pain treatment. From the panel testing it was incidentally found the patient may be at higher clot risk from standard 
cancer prophylactic, hormone therapy as well as possible future cardiac therapy. 
Conclusion: PGx panel testing may not only uncover potential medication related problems (MRPs) with the primary medical indication 
being tested, it may also refine therapy for other medical problems, resulting in avoidance of future MRPs and the health care costs 
associated with them.   
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Introduction 
As pharmacogenomics (PGx) testing has become more 
extensive, less expensive and more available, there has been a 
trend in using panels for testing.1-2 Some concerns with panel 
testing include the varying degrees of evidence available for the 
genes tested for on a given panel and the higher cost associated 
with a panel testing, especially if genes are not related to a 
patient’s specific condition being treated.3-5 Some literature 
indicates PGx panel testing  may be a cost effective strategy for 
patient treatment.2, 6-7 In this example of PGx panel testing, 
significant, actionable results were found incident to the 
primary objective of the pharmacist PGx consult. 
 
Here we present a patient with breast cancer that underwent 
previous PGx testing while participating in a PGx study for 
better pain management therapy after breast cancer surgery. 
Though the primary objective of the PGx lab panel testing was 
pain management, the panel revealed indicators of possible 
increased clot risk through Factor V Leiden thrombophilia (F5) 
and CYP2C19 intermediate metabolizer status.3,8 These results 
may impact breast cancer prophylaxis (PPx) therapy after 
breast surgery.8 Secondarily, as a CYP2C19 intermediate 
metabolizer, inability to convert clopidogrel to the active form  
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may increase clotting, even with treatment after a cardiac 
event or stroke.3 Standard breast cancer PPx therapy after 
surgery is tamoxifen or an aromatase inhibitor (AI)  such as 
letrozole, anastrozole or exemestane. Though this patient had 
normal CYP2D6 activity, tamoxifen is thought to have a higher 
risk of thrombosis than AIs and patients with F5 and a history of 
clots may be at even higher risk.9-10 The impact of the non-
conversion of clopidogrel to the active form as a CYP2C19 
intermediate metabolizer is more relevant since she is at a 
higher risk for clot formation due to her F5 status   
 
Setting 
The practice setting is an interdisciplinary, pharmacist office 
practice located in a multi-specialty, tertiary care clinic in 
Florida. The clinic offers pharmacist-provided medication 
therapy management (MTM), including more advanced PGx 
services to all patients in the clinic via referral from physicians 
and other providers with ordering privileges. More advanced in 
this case is defined as PGx results applied to comprehensive 
medication reviews (CMRs), including herbal supplements and 
cannabis products. The pharmacist-run PGx service sees 
patients from more than 20 different departments and is 
considered a specialty service, similar to other specialty 
services within the clinic. The PGx pharmacist patient visits 
occur within the provider offices to review PGx lab results. 
(Table I)  
 
Case Report 
Patient is a 52-year-old white female with newly discovered 
breast cancer. The breast tumor was discovered incidentally. 
Surgery was performed to remove the tumor and patient was 
scheduled to see the pharmacist for a PGx consult the next day. 
Previously, her surgeon enrolled her in a PGx study and ordered 
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PGx testing to assist in pain management post-surgery. (Table 
I) This surgeon is an institution PGx champion and has 
discovered panels are useful in pain management post-op and 
in the discovery of unrelated, actionable medication related 
problems (MRPs). The ordering of the panel testing begins with 
an order being placed in the electronic medical record (EMR). 
The patient then either goes to the onsite lab to provide a cheek 
swab DNA sample or a lab kit is sent to the patient’s home for 
them to provide the cheek swab sample there to mail back to 
the lab. If the sample is obtained at home, a return envelope is 
provided the patient in the lab kit so they can return the sample 
to the lab. Onsite lab results are available in as little as eight 
days, kits sent to the patient’s home usually takes two to three 
weeks. This patient was enrolled in a pain study and the 
incidental findings of this case occurred when the patient was 
interviewed as a study patient. 
 
A PGx panel of 27 genes was utilized and findings reviewed with 
the patient by the PGx pharmacist. A sample of what such a 
panel would look like is provided. (Figure I) Though there were 
no significant gene-drug interactions associated with pain 
management, significant, incidental findings were discovered 
relating to other current and potentially future therapies.  
Notably after PGx panel testing, the patient was found to be at 
increased risk of thrombosis associated with Factor V Leiden 
(F5). Intermediate CYP2C19 status indicated  poor conversion 
of clopidogrel to the active form to prevent clotting with 
clopidogrel treatment.  Upon interacting with the patient it was 
also discovered she had clot formation after a previous surgical 
procedure.  
 
PGx panel testing indicated she is an extensive (normal) 
metabolizer of CYP2D6. CYP2D6 is the primary gene that 
produces the enzyme converting tamoxifen from the inactive 
form to the active form endoxifen.3  This active form competes 
with estrogen for receptor sites in certain breast cancers to 
block the proliferative effect on cancer cell growth.11 Tamoxifen 
is standard therapy in patients who have had breast cancer 
surgery and/or radiation treatment. It is typically taken for 5 
years after initial treatment for cancer PPx to prevent the 
cancer from recurring.11 CYP2D6 normal metabolizers 
metabolize tamoxifen normally so there is usually no reason to 
not use tamoxifen cancer recurrence PPx.3  
 
Discussion 
According to CPIC guidelines, an extensive CYP2D6 metabolizer 
should use tamoxifen for PPx therapy after breast cancer 
surgery. However, the incidental findings from the PGx panel 
for this patient and past medical history revealed an F5 patient 
with a history of clotting. With tamoxifen having a higher risk of 
clots than AIs, tamoxifen use was reconsidered. As 
recommended by the PGx pharmacist, the patient was started 
on the aromatase inhibitor anastrozole for breast cancer PPx. 
In this patient, PGx panel testing revealed three important 
therapeutic issues that may not have been discovered 
otherwise. The first was a possible explanation of previous 
clotting after a past surgical procedure. Second, an F5 positive 
finding on her PGx results guided therapy away from the higher 
clot risk tamoxifen to the lower clot risk aromatase inhibitor, 
anastrazole.8 And finally, intermediate CYP2C19 status 
disqualifies future clopidogrel use if there is a future indication 
and indicates the use of prasugrel or ticagrelor.3 It is imperative 
that if the patient would require an antiplatelet therapy in the 
future, clopidogrel would not be used due to the inability for 
the patient to activate the drug.  This is especially important 
given the patient’s increased risk for thrombosis owing to their 
F5 status. F5 deficiency has been shown to increase myocardial 
infarction (MI) risk and standard therapy after MI is 
clopidogrel.11-12 
 
Using a multi-gene panel versus a single gene testing may also 
limit health care costs. Most PGx testing is permanent so results 
may be used for the patient’s lifetime without retesting. Panel 
testing may help predict future  MRPs and provide an 
opportunity to avoid them, thus saving health care dollars 
resulting from decreased emergency room visits and 
hospitalizations. Incidental costs saved would be the cost of PGx 
retesting if a single gene was tested versus a panel of genes. 
 
Case Summary 
Patient was enrolled for a PGx panel study for guided pain 
management post-surgery for a breast cancer mass. The PGx 
panel was intended for pain management after surgery. 
Incidental findings from the PGx panel results revealed that the 
patient was at greater clot risk due to F5 status with normal 
post-surgery breast PPx therapy tamoxifen. As such, the PPx 
therapy was changed to the alternative aromatase inhibitor, 
anastrozole. The patient’s PGx panel also confirmed the need 
to avoid future therapy with clopidogrel if this agent is ever 
warranted because of dual factors of F5 with clotting and 
CYP2C19 intermediate metabolizer status.  
 
Conclusion 
PGx panel testing is controversial with regard to utility and third 
party payment because of varying levels of evidence and non-
specificity of the panel to targeted therapy. Patient’s original 
indication for testing was for pain management. However, 
multiple other MRPs were discovered with PGx panel testing 
when the primary objective of the PGx lab test results was 
unremarkable. With only single gene, CYP2D6, PGx lab testing 
alone, this patient’s post-cancer treatment PPx therapy may 
have been straightforward.  However, the case demonstrates 
that even in a seemingly straightforward case of established 
treatment, mitigating factors from PGx panel testing may be 
incidentally discovered that may further refine therapy to attain 
better therapeutic outcomes or to avoid possible, future 
adverse drug reactions. PGx panel testing can also save health 
care dollars by avoiding future emergency room visits, 
hospitalizations or retesting genes in the future for other 
indications.  
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Table I 
 Relevant Patient PGx Results 
Gene Function Genotype Phenotype Interpretation 
CYP2C19 PK drug metabolism  *1/*2 Intermediate Decreased activity. Drugs converted to active 
metabolite(s) may have reduced efficacy. Active 
drugs converted to inactive metabolite(s) may 
cause side effects or toxicity 
CYP2D6 PK drug metabolism  *1/*2A Extensive (Normal) Normal level of activity. Drugs metabolized at a 
normal rate 
F5 PD (Clotting) rs6025 GA Increased risk Increased risk of thrombosis associated with 
Factor V Leiden thrombophilia versus normal risk 
OPRM1 PD activity (Pain) rs1799971 AA Minimal gene-drug 
interaction 
OPRM1 Asn/Asn (AA) genotype associated with 
normal to increased sensitivity to the analgesic 
effects of alfentanil, codeine, fentanyl, 
morphine, and tramadol compared to patients 
with the OPRM1 AG or GG genotypes at 
rs1799971. 
COMT PD activity (Pain) rs4680 GG Minimal gene-drug 
interaction 
COMT activity with GG genotype is predicted to 
be normal 
Note:  
Nomenclature for genotypes can be the * alleles from each parent separated by a slash (i.e. *1/*2) or single nucleotide 
polymorphism (SNP) at a marked gene location (i.e. SNP = GA, location = rs6025) 
Source of genotype, interpretation: www.OneOme.com14 
PK = Pharmacokinetic, PD = Pharmacodynamic 
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